Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples